3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: A cross-sectional quality-of-life survey

Acta Oncologica

Volumn 45, Issue 6, 2006, Pages 708-716

  Vordermark, Dirk ^a   Wulf, Jorn ^a   Markert, Klaus ^b   Baier, Kurt ^a   Kö Lbl, Oliver ^a   Beckmann, Gabriele ^a   Bratengeier, Klaus ^a   Noe, Michael ^b   Schö N, Georg ^b   Flentje, Michael ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Department of Urology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRACHYTHERAPY; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; CROSS-SECTIONAL STUDY; HUMAN; MALE; METHODOLOGY; PROSTATE TUMOR; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RADIATION RESPONSE;

BRACHYTHERAPY; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIATION DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 34347205773     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600710913     Document Type: Article

References (27)

1. Galalae RM, Martinez A, Mate T, Mitchell C, Edmundsun G, Nuernberg N, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58:1048-55 (Pubitemid 38314785)
2. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105 (Pubitemid 34787842)
3. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: An update of the Fox Chase experience. J Urol 2004;171: 1132-6 (Pubitemid 38327542)
4. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-6 (Pubitemid 34787844)
5. Aebersold DM, Isaak B, Thalmann G, Behrensmeier F, Kolotas C, Kranzbuhler H, et al. Applicability and dosimetric impact of ultrasound-based preplanning in high-dose rate brachytherapy of prostate cancer. Strahlenther Onkol 2004;180:351-7 (Pubitemid 38720330)
6. Martin T, Baltas D, Kurek R, Roddiger S, Kontova M, Anagnostopoulos G, et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer: A pilot study. Strahlenther Onkol 2004;180:225-32 (Pubitemid 38461547)
7. Wahlgren T, Nilsson S, Ryberg M, Lennernas B, Brandberg Y. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localised prostate cancer: A prospective assessment of acute and late treatment toxicity. Acta Oncol 2005;44:633-43 (Pubitemid 41503611)
8. Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol 2003; 169:1653-61 (Pubitemid 36443466)
9. Egawa S, Shimura S, Irie A, Kitano M, Nishiguchi I, Kuwao S, et al. Toxicity and health-related quality of life during and after high-dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 2001;31: 541-7 (Pubitemid 33138239)
10. Galalae RM, Loch T, Riemer B, Rhezak P, Kuchler T, Kimmig B, et al. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer. Strahlenther Onkol 2004;180:582-9 (Pubitemid 39248791)
11. Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Shortcourse intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001;51:988-93 (Pubitemid 33026429)
12. Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose escalastion study. Urology 2003;62:707-13 (Pubitemid 37205010)
13. Wahlgren T, Brandberg Y, Häggarth L, Hellström M, Nilsson S. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with 192Ir brachytherapy: A prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25. Int J Radiat Oncol Biol Phys 2004;60:51-9 (Pubitemid 39165468)
14. Mc Neal JF. The zonal anatomy of the prostate. Prostate 1981;2:35-49
15. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76 (Pubitemid 23073154)
16. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001;37:1345-51 (Pubitemid 32588744)
17. Aaronson NK, van Andel G. An international field study of the reliability and validity of the QLQ-C30 and a diseasespecific questionnaire module (QLQ-PR25) for assessing quality of life of patients with prostate cancer. European Organization for Research and Treatment of Cancer study protocol 15011. Brussels: 2002
18. Fayers PM, Aaronson NK, Bjordal K, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. European Organisation for Research and Treatment of Cancer. Brussels: 2001
19. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Using reference data on quality of life-the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (-3). Eur J Cancer 1998;34:1381-9 (Pubitemid 28370930)
20. Gulbrandsen N, Hjermstad MJ, Wisloff F, Nordic Myeloma Study Group. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004;72: 172-80 (Pubitemid 38250794)
21. Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004;43:316-81 (Pubitemid 38887858)
22. Vordermark D, Flentje M. Planning target volume definition in dose-escalation studies. Front Radiat Ther Oncol 2002; 36:16-24
23. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44 (Pubitemid 28041591)
24. Ott C, Fulton MK. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer. J Am Acad Nurse Pract 2005;17:113-22
25. Zelefsky MJ, Cowen D, Fuks Z, Venkatraman ES, Cowen DM, Levegrun S, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999;85:2460-8 (Pubitemid 29244857)
26. Hoskin PJ. High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. Radiother Oncol 2000;57:285-8
27. Boehmer D. Multi-center phase III trial on combined interstitial high-dose-rate brachytherapy plus external-beam radiotherapy versus external-beam radiotherapy alone in patients with locally advanced prostate cancer. Berlin: 2006